PolTREG

Dear Investors, we invite you to an online meeting with the Management Board of PolTREG to discuss the Company’s current operational activities and development outlook for the coming quarters.

Participants:
Prof. Piotr Trzonkowski – President of the Management Board, CEO
Mariusz Jablonski – Member of the Management Board

Date: December, 10 2025 (Wednesday)
Time: 12:00 PM

Registration link: https://ccgroup.clickmeeting.com/poltreg-s-a-3q-2025/register
Registration is required – you will receive an email with your individual access link.
----------------------------------------------------------------------------------
Zapraszamy na spotkanie online z Zarządem PolTREG poświęcone omówieniu bieżących działań operacyjnych oraz perspektyw rozwoju w kolejnych kwartałach.

w spotkaniu udział wezmą:
Prof. Piotr Trzonkowski - Prezes Zarządu, CEO
Mariusz Jabłoński - Członek Zarządu

data: 10 grudnia 2025 (środa)
godzina: 12:00

Link rejestracyjny: https://ccgroup.clickmeeting.com/poltreg-s-a-3q-2025/register
Wymagana jest rejestracja na spotkanie - otrzymacie Państwo e-mail z indywidualnym linkiem dostępowym.

We’re so thrilled to announce the publication of our clinical data analysis confirming long-term safety and efficacy of PolTREG S.A.’s autologous Treg-based therapy for type 1 diabetes!

The study clearly documented that our therapy delays onset of T1D symptoms and works even 12 years after receiving the therapy. This is the longest follow-up of Treg-treated T1D patients ever published and a major step for the field. It shows that a well-crafted Treg product can deliver durable immune balance and help preserve beta-cell function long after treatment.

We enrolled 51 participants who took part in our clinical trials as children, so are now young adults who are 7.5 to 12 years after the administration of Tregs or standard of care therapy.

The results speak clearly:
- No severe adverse events, no tumors, no treatment-related safety issues - even a decade later.
- Sustained clinical benefit: higher C-peptide, longer remission and insulin-independence compared to standard care.
- The Tregs + anti-CD20 regimen delivered the strongest outcomes.

A big thank you to the patients, clinical teams, and everyone at PolTREG S.A. driving this work forward. The future of Treg therapy in T1D looks promising and we’re pushing it even further.

The study, conducted by the Gdański Uniwersytet Medyczny (Medical University of Gdańsk) and PolTREG S.A., followed patients 7.5–12 years after receiving autologous Tregs as children.

Full article (open access) in Diabetes, Obesity and Metabolism is available here: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70330

We’re pleased to announce that the Korean Intellectual Property Office has granted AZTherapies a new patent for the use of CAR-Treg therapy in autoimmune neurodegenerative diseases. PolTREG holds the exclusive global license for these innovative cellular therapies across all indications.

This CAR-Treg project is also protected by patents in Australia, the USA, and Japan.

PolTREG continues to advance one of the most comprehensive platforms for Treg-based therapies, including polyclonal Treg, CAR-Treg, allogeneic Treg, antigen-specific Treg, and TCR-Treg – driving the future of immune regulation therapies.